TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Staphylococcal Skin Infection Clinical Trial

Official title:
A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

Clinical Trial Description

TD-1792 is compared to vancomycin for the treatment of cSSSI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00442832
Study type	Interventional
Source	Theravance Biopharma
Contact
Status	Completed
Phase	Phase 2
Start date	December 2006
Completion date	May 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00352612` - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections	Phase 4
Completed	`NCT00091819` - Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus	Phase 3
Completed	`NCT00107978` - Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus	Phase 3
Completed	`NCT01814371` - Individualized vs. Household MRSA Decolonization	N/A